| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
|
Moreno, Lucas
|
|
|
136 |
C |
p. 52-68
|
article
|
| 2 |
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
|
Gougis, Paul
|
|
|
136 |
C |
p. 1-3
|
article
|
| 3 |
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study
|
de Vries-Brilland, Manon
|
|
|
136 |
C |
p. 76-83
|
article
|
| 4 |
BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study
|
Kitson, Sarah J.
|
|
|
136 |
C |
p. 169-175
|
article
|
| 5 |
Corrigendum to ‘Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial’ [Eur J Canc 124 (January 2020) 25–36]
|
Schmitz, Christine
|
|
|
136 |
C |
p. 207-208
|
article
|
| 6 |
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
|
Houot, Roch
|
|
|
136 |
C |
p. 4-6
|
article
|
| 7 |
COVID-19, palliative care and public health
|
Rodin, Gary
|
|
|
136 |
C |
p. 95-98
|
article
|
| 8 |
Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings
|
Castañon, Eduardo
|
|
|
136 |
C |
p. 159-168
|
article
|
| 9 |
Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer
|
Angelis, Vasileios
|
|
|
136 |
C |
p. 99-106
|
article
|
| 10 |
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial
|
Conte, Benedetta
|
|
|
136 |
C |
p. 43-51
|
article
|
| 11 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
|
Rinaldi, Yves
|
|
|
136 |
C |
p. 25-34
|
article
|
| 12 |
Genetic variants in TKT and DERA in the nicotinamide adenine dinucleotide phosphate pathway predict melanoma survival
|
Gu, Ning
|
|
|
136 |
C |
p. 84-94
|
article
|
| 13 |
High-dose chemotherapy in a patient with coronavirus disease (COVID-19)
|
De Giorgi, Ugo
|
|
|
136 |
C |
p. 130-131
|
article
|
| 14 |
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer
|
van der Doelen, Maarten J.
|
|
|
136 |
C |
p. 16-24
|
article
|
| 15 |
Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective
|
de Joode, K.
|
|
|
136 |
C |
p. 132-139
|
article
|
| 16 |
Innovative countermeasures can maintain cancer care continuity during the coronavirus disease-2019 pandemic in Korea
|
Lee, Soohyeon
|
|
|
136 |
C |
p. 69-75
|
article
|
| 17 |
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy
|
Dieci, Maria Vittoria
|
|
|
136 |
C |
p. 7-15
|
article
|
| 18 |
Making sense of cross-trial comparisons for the frontline treatment of advanced-stage Hodgkin lymphoma
|
Lad, Deepesh P.
|
|
|
136 |
C |
p. 113-115
|
article
|
| 19 |
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents
|
Pearson, Andrew D.J.
|
|
|
136 |
C |
p. 116-129
|
article
|
| 20 |
Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors
|
Iacovelli, Roberto
|
|
|
136 |
C |
p. 195-203
|
article
|
| 21 |
Ponatinib in childhood Philadelphia chromosome–positive leukaemias: an international registry of childhood chronic myeloid leukaemia study
|
Millot, Frédéric
|
|
|
136 |
C |
p. 107-112
|
article
|
| 22 |
PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery
|
Sánchez-Iglesias, José Luis
|
|
|
136 |
C |
p. 149-158
|
article
|
| 23 |
Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands
|
Cavalieri, Stefano
|
|
|
136 |
C |
p. 35-42
|
article
|
| 24 |
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials
|
Pasalic, Dario
|
|
|
136 |
C |
p. 176-185
|
article
|
| 25 |
RE: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer
|
Howell, Sacha J.
|
|
|
136 |
C |
p. 204-205
|
article
|
| 26 |
Relapsing intracranial germ cell tumours warrant retreatment
|
Callec, Laetitia
|
|
|
136 |
C |
p. 186-194
|
article
|
| 27 |
Response to letter commenting on: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer
|
Samuel, Evangeline
|
|
|
136 |
C |
p. 206
|
article
|
| 28 |
Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours – Results from daily clinical practice
|
IJzerman, Nikki S.
|
|
|
136 |
C |
p. 140-148
|
article
|
Journal description